Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain (SODA)
This study has been completed.
Sponsor:
Medtronic Spine LLC
Information provided by (Responsible Party):
Medtronic Spine LLC
ClinicalTrials.gov Identifier:
NCT00443781
First received: March 2, 2007
Last updated: March 19, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to document and compare diagnostic test results and procedure safety in subjects undergoing both Functional Anaesthetic DiscographyTM (F.A.D.) and provocative discography (PD) and determine the appropriateness of the F.A.D. procedure data collection script for use in a larger clinical trial.
| Condition | Intervention | Phase |
|---|---|---|
|
Low Back Pain |
Procedure: functional anesthetic discography Procedure: provocative discography |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain |
Resource links provided by NLM:
Further study details as provided by Medtronic Spine LLC:
Primary Outcome Measures:
- Difference in Number of Magnetic Resonance Imaging (MRI)-Positive Discs Diagnosed Positive by Provocative Discography (PD) and Functional Anesthetic Discography (F.A.D.) [ Time Frame: Approximately 2 hours per subject ] [ Designated as safety issue: Yes ]For provocative discography (PD), a positive response at an individual disc requires all of the following findings: pain intensity (>=7/10 on 0-10 Numerical Rating Scale, NRS) as rated by subjects on injecting contrast into a disc; concordancy (pain reproduces typical back pain exactly). For Functional Anesthetic Discography (F.A.D.), a positive test at an individual disc level is defined as improvement in self-rated pain of >=2 Numerical Rating Scale (NRS) points AND >33% on 0-10 Numerical Rating Scale 10 minutes after injection of lidocaine.
| Enrollment: | 62 |
| Study Start Date: | March 2007 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| PD and F.A.D. diagnostic testing |
Procedure: functional anesthetic discography
Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
Procedure: provocative discography
Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as ("concordant") or different from ("not concordant" or "discordant") typical back pain.
|
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age > 21.
- Chronic axial low back pain without radicular pain for > six months, not responding to at least three months of non-surgical management under the direction of a physician.
- One or two discs at L5/S1, L4/L5 or L3/L4 with abnormal findings by MRI, including any of the following: loss of disc hydration, loss of disc height, high intensity zone (HIZ), Modic changes at adjacent vertebral endplates, or herniation without nerve root compression.
- Subject states that he/she is willing to undergo lumbar spinal fusion, disc replacement, or other definitive treatment if eventual diagnosis supports such treatment.
- Physician believes that discography is clinically indicated for the purpose of surgical decision-making for the subject.
- Pre-treatment low back pain by numerical rating scale (NRS) score > 4 (measured as average in last 24 hours on a 0-10 scale).
- Pre-treatment Oswestry Disability Index (ODI) > 40 (0 - 100 scale).
- Subject states availability for all study visits.
- Subject is able to understand the risks and benefits of participating in the study and provides written informed consent.
Exclusion Criteria:
- Known osteoporosis or osteopenia, metabolic bone disorder, or history of chronic steroid use (the equivalent of 7.5 milligrams of daily prednisone use for > 6 months).
- Suspected painful disc degeneration (based on clinical examination and MRI findings) outside of L5/S1, L4/L5 or L3/L4 levels.
- MRI shows disc abnormalities (listed in Inclusion Criteria #3) at all 3 lower lumbar discs (L3/L4, L4/L5 and L5/S1).
- Abnormal neurologic exam attributable to lumbar disc disease, herniation, or lumbar stenosis.
- Back, buttock or pelvic pain suspected to be due to spinal stenosis, spinal fractures, infection, cancer, facet arthropathy or other hip or pelvis pathology.
- Schmorl's node or endplate disruption evident on MRI at L5/S1, L4/L5, or L3/L4.
- Medical history, physical examination or radiographic evidence (e.g., disc height too narrow) to suggest that either PD or F.A.D. may not be technically feasible.
- Any previous lumbar spine fusion or disc replacement.
- More than grade 1 spondylolisthesis as assessed by x-ray or MRI.
- Significant clinical comorbidity that may potentially interfere with data collection or follow-up (e.g., dementia, severe comorbid illness).
- History of major depression, psychosis or somatization disorder, or panic disorder.
- Allergy to any materials used in PD or F.A.D. devices, contrast, lidocaine, or bupivacaine.
- Any evidence of disc or systemic infection.
- Pregnant or child-bearing potential and not currently on adequate birth control method.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00443781
Locations
| United States, Alabama | |
| The Spine and Neurosurgery Center | |
| Huntsville, Alabama, United States, 35801 | |
| United States, California | |
| Spine Source | |
| Beverly Hills, California, United States, 90212 | |
| Pacific Spine Clinic | |
| Escondido, California, United States, 92025 | |
| UCSD Orthopaedic Surgery | |
| San Diego, California, United States, 92103 | |
| United States, Georgia | |
| Emory Orthopaedics & Spine Center | |
| Atlanta, Georgia, United States, 30329 | |
| United States, Pennsylvania | |
| Hanover Orthopaedic Associates, Inc. | |
| Hanover, Pennsylvania, United States, 17331 | |
| United States, Texas | |
| Texas Back Institute | |
| Plano, Texas, United States, 75093 | |
| East Texas Medical Center | |
| Tyler, Texas, United States, 75701 | |
| United States, Washington | |
| Evergreen Surgical Center | |
| Kirkland, Washington, United States, 98034 | |
| United States, Wisconsin | |
| Milwaukee Neurological Institute | |
| Milwaukee, Wisconsin, United States, 53233 | |
Sponsors and Collaborators
Medtronic Spine LLC
Investigators
| Principal Investigator: | Ray M Baker, MD | University of Washington |
| Principal Investigator: | Rick D Guyer, MD | Texas Back Institute, Plano, TX |
More Information
No publications provided
| Responsible Party: | Medtronic Spine LLC |
| ClinicalTrials.gov Identifier: | NCT00443781 History of Changes |
| Other Study ID Numbers: | SP0603 |
| Study First Received: | March 2, 2007 |
| Results First Received: | June 23, 2010 |
| Last Updated: | March 19, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Medtronic Spine LLC:
|
low back pain, degenerative disc disease |
Additional relevant MeSH terms:
|
Back Pain Low Back Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms |
Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013